Biocytogen Announces RenLite® Licensing Agreement with Janssen
8.3.2023 16:25:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services Partners with Anthropic to Deliver AI-Powered Engineering Intelligence for Products and Manufacturing14.7.2026 18:28:00 EEST | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced a partnership with Anthropic to accelerate Engineering Intelligence by integrating Claude models across engineering processes and LTTS’ AI-powered platforms. The collaboration will help LTTS’ enterprise clients redesign how products and software are developed, enabling faster innovation and improved outcomes at scale. Leveraging Claude across the engineering lifecycle and uniting deep engineering expertise, advanced AI and domain knowledge, LTTS’ Engineering Intelligence discipline will enable clients to create greater value. Rather than automating individual tasks, it enables teams to make faster decisions, streamline workflows and continuously improve how products, manufacturing plants and industrial systems are designed, built and maintained. By integrating Claude models into its platforms including AgenticIQ, PlxAI, Ainfonix™, A
Presidio Investors Announces Sale of ElevATE Semiconductor to Diodes Incorporated14.7.2026 17:56:00 EEST | Press release
Presidio Investors (“Presidio”), a lower middle market private equity firm, today announced that it has entered into a definitive agreement to sell ElevATE Semiconductor, Inc. (“ElevATE”) to Diodes Incorporated (Nasdaq: DIOD) in an all-cash transaction valued at $250 million. ElevATE, headquartered in San Diego, California, is a leading fabless designer of low-power, high-density integrated circuits for the automated test equipment (ATE) industry. The sale marks the successful realization of Presidio’s first continuation fund, which was formed in 2023 to extend the firm’s partnership with ElevATE and support the company’s next phase of growth. The acquisition of ElevATE by a leading global semiconductor company validates the strategy behind the continuation vehicle and delivers a strong outcome for the company, its employees, and Presidio’s investors. Presidio first invested in ElevATE in 2018, when the company was a small, founder-led team of analog chip designers serving the ATE mark
Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition to make EAA AirVenture show debut14.7.2026 17:30:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition are heading to the 2026 Experimental Aircraft Association (EAA) AirVenture in Oshkosh, Wisconsin. Both aircraft will be on display for the first time at the show alongside a broad lineup of Cessna and Beechcraft aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714774354/en/ Cessna Citation CJ3 Gen2 and Beechcraft King Air 360 Crimson Edition to make EAA AirVenture show debut “EAA AirVenture is one of the most important opportunities each year for us to connect with customers and the broader aviation community,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Being on the ground in Oshkosh allows us to showcase the breadth of our portfolio. Events like AirVenture also give us valuable face-to-face time to better understand how our customers operate and
Clearlake Capital Announces Partnership with Databricks to Advance AI-Enabled Investing and Portfolio Value Creation14.7.2026 17:00:00 EEST | Press release
Clearlake Capital Group, L.P. ("Clearlake"), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced a partnership with Databricks, the Data and AI company, and West Monroe, a global business and technology consulting firm, to accelerate Clearlake’s portfolio companies’ adoption of data, analytics, and AI capabilities. Through the collaboration, Clearlake aims to connect investment, operational, financial, and portfolio data in a secure and scalable environment that accelerates enterprise-wide adoption of AI, drives productivity, and delivers measurable outcomes across the investment lifecycle from deal origination and due diligence to portfolio monitoring and value creation. By pairing cutting-edge technology with deep operational support, the partnership endeavors to help Clearlake’s portfolio companies stay ahead of industry disruption and build durable competitive advantage. “Data and A
Andersen Consulting Deepens Advisory Solutions in Turkey with ODS Consulting Group14.7.2026 16:30:00 EEST | Press release
Andersen Consulting adds collaborating firm ODS Consulting Group, enhancing its platform across digital transformation, talent strategy, and operational advisory services. Founded in 2008 and headquartered in Turkey, ODS Consulting Group provides advisory services to organizations seeking growth, talent, and investment opportunities in Turkey and international markets. The firm supports clients through international business development and export consulting, recruitment and talent management solutions, and investment advisory services, helping businesses expand operations, access new markets, attract qualified talent, and navigate the Turkish business landscape. With a multidisciplinary approach and deep local expertise, ODS delivers tailored strategies that drive sustainable growth and long-term value creation. “Since our founding, we have focused on helping organizations build sustainable growth through a combination of strategic insight and practical execution,” said Onur Seçkin, c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom